cabozantinib,nivolumab,ipilimumab
exelixis,bms
['ipilimumab', 'nivo', 'cabozantinib', 'triplet,(-triplete)', 'nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic-313', 'rs onco']
#esmo22 video: watch our interview with ( ) about the first results from the cosmic-313 trial evaluating the cabozantinib, nivolumab and ipilimumab triplet in treatment-na ve patients with advanced rcc 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.